Last updated on November 2017

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy


Brief description of study

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Detailed Study Description

To compare the efficacy of once daily injections in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Patient Inclusion Criteria:

  • Cancer patients with metastatic or locally advance solid tumor of the lung, pancreas, stomach, colon/rectum, bladder or ovary, planned to start a new course of chemotherapy with a minimum intent of 3 months therapy

Patient Exclusion Criteria:

  • Life expectancy of less than 3 months, any major surgery within the last 4 weeks or planned during the study treatment period, any treatment with other anti-thrombotic agents within 2 weeks prior to randomization

Clinical Study Identifier: TX792

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Dr. Tom Davis

Legacy Pharma Research
Bismarck, ND USA
  Connect »